logo
Plus   Neg
Share
Email

Atlas Air Worldwide Updates Outlook, Q3 Profit Misses Estimates; Stock Plunges

Atlas Air Worldwide Holdings, Inc. (AAWW) announced the company now anticipates full-year 2019 revenue of approximately $2.75 billion; adjusted EBITDA of approximately $500 million; and adjusted net income, including a benefit, to be about 60-65 percent of 2018 adjusted net income. Analysts polled by Thomson Reuters expect the company to report revenue of $2.86 billion.

Third-quarter adjusted income per share from continuing operations was $0.37, compared to $1.54, a year ago. On average, eight analysts polled by Thomson Reuters expected the company to report profit per share of $1.02, for the quarter. Analysts' estimates typically exclude special items.

Third-quarter operating revenue was $648.54 million compared to $656.61 million, previous year. Analysts expected revenue of $699.08 million, for the quarter.

Shares of Atlas Air Worldwide were down nearly 11% in pre-market trade on Wednesday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
PG&E agreed to pay around $13.5 billion to settle all individual claims related to California wildfires, due to which the electric utility had to file for bankruptcy. With the Bankruptcy Court's approval of the settlement agreement, PG&E hopes to emerge from Chapter 11 by the June 30, 2020 deadline to participate in the State of California's go-forward wildfire fund. Airbnb has introduced few new rules to control parties and nuisances amidst the backlash the service received after the Halloween shooting at an Airbnb rental in a San Francisco. San Francisco-based Airbnb said it is banning "open invite" parties at all of its accommodations. The company is also banning... The U.S. Food and Drug Administration has approved three generic versions of Novartis' Gilenya capsule for treating relapsing forms of multiple sclerosis. "Approving safe and effective generics so patients have more treatment options continues to be a priority for the FDA," said Janet Woodcock, director...
Follow RTT
>